News | January 12, 2023
Apollo Genomics Institutes launched at Apollo Hospitals Navi Mumbai
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
